Report: the global market of anticancer drugs will reach 150 billion US dollars in 2020

Source: Biovalley 2016-06-06 recently, IMS Health, a famous pharmaceutical industry professional information and strategic consulting company, released a global cancer trend report, summarizing the types, prices and market scope of new cancer drugs approved in 2015, pointing out that by 2020, the global cancer drug market will reach US $150 billion Now let's introduce the main contents of this report In recent years, with the increasing number of tumor patients and the deepening of scientific understanding of tumor, the field of tumor medicine is changing rapidly Many medical and health departments are trying to adapt to this change, especially drug regulatory departments, diagnosis and treatment institutions and medical insurance institutions, all need to constantly adjust strategies to meet the actual needs of more and more cancer patients In the past five years, 70 new cancer drugs have been approved in more than 20 different tumor types However, most of them are only sold in a limited number of countries or recognized by drug regulatory authorities, but they cannot be accepted by medical cost control agencies For example, some heavy cancer drugs have been approved by the European Commission, but they cannot be approved by nice, so patients There is no access to new drugs According to statistics, in 2015, the global total cost of cancer treatment and adjuvant treatment was US $107 billion, up 11.5% from 2014 It's not hard to understand why medical cost control departments spend a lot of energy to evaluate the cost performance of new drugs and the right treatment targets, after all, tumor drugs are too expensive Ames estimates that the overall tumor drug market will maintain such an upward trend in the next five years Highlight 1: from 2011 to 2015, 70 new cancer drugs have been approved from 2011 to 2015 A total of 70 new cancer drugs have been approved in more than 20 tumor types, and most of them are still in follow-up clinical trials and are expected to be approved in more indications Highlight 2: from 2005 to 2015, research and development of tumor industry increased by 63% According to Ames, in the past 10 years, 586 molecules have entered clinical research and development, an increase of 63% over the previous stage; of these 586 molecules, 87% are targeted drugs In the past 10 years, the focus of research and development has been on tumor specific targets In recent years, tumor immunotherapy has also begun to rise More than 500 companies are active in the research and development of cancer drugs, including Roche, AstraZeneca, Bristol Myers, MSD, Pfizer and other pharmaceutical giants, as well as kit, Juno and other emerging companies Highlight 3: the tumor drug market continues to expand In 2015, the global market reached $107 billion In the past five years, the annual compound growth rate of the global tumor drug market was 7.4%, slightly lower than the 8.3% in the previous five years The compound annual growth rate of tumor drugs was 9.8%, while that of adjuvant drugs was only 0.7% Highlight 4: in 2020, the global tumor drug market will exceed 150 billion US dollars With the continuous increase of product indications, the price of tumor drugs is also rising, especially tumor immunotherapy Due to the limited types of approved drugs, the effect is very significant, and the price is also very impressive Many anticancer drugs face the embarrassment of patent cliff, and the impact of generic drugs is more and more obvious, these factors will reduce the price of anticancer drugs to a certain extent But overall, with the increase of incidence rate, diagnosis rate and treatment rate, the market of anticancer drugs will show an overall trend of increase.